Coated Capsules Patents (Class 424/463)
-
Publication number: 20150140091Abstract: A solid dispersion comprising at least one active ingredient in at least one hydroxyalkyl methylcellulose having a DS of from 1.0 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, can be produced by extrusion or spray-drying.Type: ApplicationFiled: July 12, 2013Publication date: May 21, 2015Applicant: Dow Global Technologies LLCInventors: Nicholas S. Grasman, Steven J. Guillaudeu, Mark J. Hall, Uma Shrestha, Maureen L. Rose, William W. Porter, III, Wesley J. Spaulding, Kevin P. O'donnell, True L. Rogers
-
Publication number: 20150141901Abstract: A method of increasing bone marrow stem cells in the blood stream, and targeting those stem cells toward specific damaged or diseased organs in the body so that the tissue in these organs might be repaired. The method comprises ingestion of a claimed formulation having effective amounts of Aphanizomenon flos-aquae and fucoidan being released into the blood stream over a measured period of time, and during that period, irradiating the ribs, skull, vertebrae, or pelvic bones, as well as the damaged or diseased area with low-level laser therapy. The combination of ingesting the formulation and the low-level laser therapy causes the release of bone marrow pluripotent stem cells, which then transform into the targeted tissue cells, thereby repairing the damaged or diseased tissue.Type: ApplicationFiled: November 6, 2014Publication date: May 21, 2015Inventors: Alan S. Lichtbroun, Michael Lichtbroun, Stanley H. Kremen
-
Publication number: 20150132377Abstract: A capsule delivery system. The system has a first capsule containing a first capsule wall encapsulating a first active material and a second capsule containing a second capsule wall encapsulating a second active material. The first and second capsules differ in their wall materials, amounts of wall materials, ratios of wall materials, core modifiers, scavengers, active materials, curing temperatures, heating rates, curing times, or a combination thereof. Also provided is a consumer product containing this capsule delivery system.Type: ApplicationFiled: November 11, 2014Publication date: May 14, 2015Inventors: Henricus Gerardus Maria Reymar, Stephanus Cornelis Maria Otte, Volkert Willem Alexander de Villeneuve, Elizabeth Geertrude Maria Brundel
-
Patent number: 9028866Abstract: It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.Type: GrantFiled: June 1, 2011Date of Patent: May 12, 2015Assignee: Geistlich Pharma AGInventors: Rolf W. Pfirrmann, Peter Geistlich
-
Publication number: 20150125522Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.Type: ApplicationFiled: September 12, 2014Publication date: May 7, 2015Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Patent number: 9023386Abstract: The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications.Type: GrantFiled: July 23, 2008Date of Patent: May 5, 2015Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Shimon Benita, Alona Rom, Taher Nasser
-
Patent number: 9023630Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: GrantFiled: October 2, 2007Date of Patent: May 5, 2015Assignee: The Invention Science Fund I, LLCInventors: Ed Harlow, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
-
Publication number: 20150118297Abstract: The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes.Type: ApplicationFiled: June 2, 2014Publication date: April 30, 2015Applicant: RITTER PHARMACEUTICALS, INC.Inventors: Andrew J. Ritter, Dennis Savaiano, David Barnes, Todd Klaenhammer
-
Publication number: 20150118299Abstract: An object of the present invention is to provide a capsule formulation comprising a phosphonooxymethyl derivative of ravuconazole which suppresses delay in dissolution due to storage regardless of an encapsulated amount of the phosphonooxymethyl derivative of ravuconazole. The present invention provides a capsule formulation comprising an encapsulated material comprising {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-ylmethyl)propyl]oxy}methyl dihydrogen phosphate or a pharmacologically acceptable salt thereof, or a solvate of any of the foregoing, and a capsule shell not comprising gelatin.Type: ApplicationFiled: April 17, 2013Publication date: April 30, 2015Inventor: Yosuke Ueki
-
Patent number: 9011908Abstract: Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.Type: GrantFiled: April 1, 2010Date of Patent: April 21, 2015Assignee: Banner Life Sciences LLCInventors: Zhi Liu, Saujanya L. Gosangari, Dana S. Toops, Aqeel Fatmi
-
Publication number: 20150104507Abstract: A modified release formulation of lacosamide.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Inventors: Willi CAWELLO, Martin Alexander SCHUBERT
-
Publication number: 20150104505Abstract: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 16, 2015Inventors: Manish S. SHAH, Ray J. DiFalco
-
Patent number: 9005944Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: GrantFiled: October 2, 2007Date of Patent: April 14, 2015Assignee: The Invention Science Fund I, LLCInventors: Ed Harlow, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
-
Publication number: 20150098992Abstract: Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite formulation can effectively charge the MUSTs in the limited space of the capsule, which allows charging a high dose of different pharmaceutically active ingredients in a capsule with a relatively small size, to thereby increase the productivity and render it readily administered to patients. Also, the capsule has a good dissolution rate because the pharmaceutically active ingredients contained in the capsule are separated from one another; therefore, the dissolution rates of the ingredients are less affected by one another. It may also be possible to maximize the therapeutic effects of the pharmaceutically active ingredients since the composite formulation has good stability.Type: ApplicationFiled: April 12, 2013Publication date: April 9, 2015Applicant: HANMI PHARM. CO., LTDInventors: Kyeong Soo Kim, Dong Ho Kim, Taek Kwan Kwon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
-
Patent number: 8999296Abstract: Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.Type: GrantFiled: April 21, 2009Date of Patent: April 7, 2015Assignees: Kochi University, SBI Pharmaceuticals Co., Ltd.Inventors: Keiji Inoue, Masahiro Ishizuka, Tohru Tanaka
-
Patent number: 8999360Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.Type: GrantFiled: October 22, 2010Date of Patent: April 7, 2015Inventors: Thomas Julius Borody, Soledad Carsula
-
Patent number: 8999383Abstract: The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.Type: GrantFiled: May 7, 2009Date of Patent: April 7, 2015Assignee: Merrion Research III LimitedInventors: Amanda Lee, Bozena Adamczyk, David C. Coughlan, Edel O'Toole, Thomas W. Leonard
-
Publication number: 20150086625Abstract: Activated fatty acids, nutraceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.Type: ApplicationFiled: December 8, 2014Publication date: March 26, 2015Inventor: Raymond A. Miller
-
Publication number: 20150086627Abstract: Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein.Type: ApplicationFiled: March 29, 2013Publication date: March 26, 2015Applicant: HALO THERAPEUTICS, LLC.Inventors: Ernest D. Bush, Diane Mcguire, Marc B. Blaustein
-
Patent number: 8986723Abstract: A composition comprising (a) a non-aqueous pourable fluid, (b) droplets dispersed in said pourable fluid (a), wherein said droplets comprise (i) a non-aqueous continuous phase that is a solid or that is a liquid of high viscosity and (ii) solid particles dispersed in said continuous phase (i), wherein said solid particles (ii) have median size as measured by the largest dimension of 100 micrometers or less, and wherein said solid particles (ii) comprise one or more cyclopropene compound and one or more molecular encapsulating agent. Also, a method of treating plants or plant parts involving bringing such a composition into contact with plants or plant parts.Type: GrantFiled: February 9, 2011Date of Patent: March 24, 2015Assignee: Rohm and Haas CompanyInventors: Richard M. Jacobson, Yueqian Zhen
-
Publication number: 20150079164Abstract: The present disclosure relates to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with acne and/or eczema (dermatitis).Type: ApplicationFiled: March 15, 2013Publication date: March 19, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras
-
Patent number: 8980320Abstract: A film coating agent for a solid formulation includes a water-soluble cellulose derivative, swelling clay, a cationic surfactant, and a fatty acid, wherein mass ratio of the swelling clay to the water-soluble cellulose derivative is 2:8 to 8:2, and content of the cationic surfactant is not less than 0.5 equivalents and not more than 3.0 equivalents relative to a cation exchange equivalent of the swelling clay.Type: GrantFiled: November 30, 2010Date of Patent: March 17, 2015Assignee: Toray Industries, Inc.Inventors: Ryoji Yoshii, Yuki Hayashi, Yuki Fujisaki
-
Patent number: 8980314Abstract: An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients include water-soluble hot melt materials selected from PEG, poloxamer, polyoxyl (40) stearate or their mixture. Based on the total weight of the core, the amount of water-soluble hot melt materials is 10%˜40% and the amount of duloxetine or its salt is 15˜60%. The core material is prepared by hot melt process. The enteric formulation comprises the core, a separating layer and an enteric layer.Type: GrantFiled: November 4, 2009Date of Patent: March 17, 2015Assignee: Shanghai Zhongxi Pharmaceutical CorporationInventors: Yunhui Ding, Siji Zheng
-
Publication number: 20150071999Abstract: Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.Type: ApplicationFiled: March 15, 2013Publication date: March 12, 2015Inventors: Yunfeng Lu, Irvin S.Y. Chen, Ming Yan, Min Liang, Masakazu Kamata, Jing Wen
-
Publication number: 20150072000Abstract: Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water.Type: ApplicationFiled: March 20, 2012Publication date: March 12, 2015Applicants: Eastbrand Holdings GMBH, Laboratorios Bago S.A.Inventor: Mario Atilio Los
-
Publication number: 20150072858Abstract: The present disclosure is directed to cellulose ether compositions for film-forming coating applications. A coating composition is provided which contains an aqueous solution of either a very low viscosity cellulose ether or a low-hydroxypropyl cellulose ether, the coating composition having low color. The low viscosity of the cellulose ether component enables the coating composition to contain a high concentration of cellulose ether. Provision of these high concentration cellulose ether coating solutions improves production efficiency by reducing the time required to coat a substrate.Type: ApplicationFiled: November 13, 2014Publication date: March 12, 2015Inventors: True L. Rogers, Debora L. Holbrook, Karen A. Coppens, Robert L. Schmitt
-
Patent number: 8974822Abstract: The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.Type: GrantFiled: June 2, 2011Date of Patent: March 10, 2015Assignee: Diffusion Pharmaceuticals LLCInventors: John L. Gainer, Robert Murray
-
Publication number: 20150064248Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Manish S. Shah, Ray J. DiFalco
-
Publication number: 20150064247Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Manish S. Shah, Ray J. DiFalco
-
Publication number: 20150056276Abstract: The present disclosure relates to pharmaceutical compositions comprising omega-3 fatty acids and vitamin D for use in at least one of preventing and treating psoriasis, and to food supplement, dietary supplement, nutritional supplement, over-the-counter (OTC) supplement, medical food, or pharmaceutical grade supplement compositions comprising omega-3 fatty acids and vitamin D for use in improving at least one parameter associated with psoriasis.Type: ApplicationFiled: March 15, 2013Publication date: February 26, 2015Applicant: Pronova Biopharma Norge ASInventors: David A. Fraser, Alexis Garras
-
Patent number: 8962004Abstract: The invention relates to compositions including an encapsulated triazinyl sulfonylurea. The invention further relates to methods for controlling weeds. The invention additionally provides methods for producing such compositions.Type: GrantFiled: April 5, 2012Date of Patent: February 24, 2015Assignee: Arysta Lifescience North America, LLCInventor: James C. Lee
-
Publication number: 20150050336Abstract: The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependent polymer and a non-plasticizing active pharmaceutical ingredient in a solvent, granulating using that material or forming layers over a solid support therewith. This can be followed with the use of a taste masking overcoating layer.Type: ApplicationFiled: October 7, 2014Publication date: February 19, 2015Inventors: Walid A. Habib, Derek V. Moe
-
Patent number: 8957053Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.Type: GrantFiled: January 7, 2014Date of Patent: February 17, 2015Assignees: Tesorx Pharma, LLC, Western University Health SciencesInventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
-
Patent number: 8951558Abstract: The invention relates to an aqueous medium containing an amino(meth)acrylate polymer or copolymer which is not soluble in dematerialised water, characterized in that the medium has a content of an aqueous phase of at least 60% by weight and a content of up to 40% by weight of solids comprising the amino(meth)acrylate polymer or copolymer, whereby the aqueous phase is charged by a sufficient amount of carbon dioxide that effects the amino(meth)acrylate polymer or copolymer to be present in solute form in the medium. The aqueous medium may be used beneficially as a coating or binding solution for the spray coating or binding of pharmaceutical compositions or nutraceutical compositions or cosmetical compositions.Type: GrantFiled: July 30, 2009Date of Patent: February 10, 2015Assignee: Evonik Röhm GmbHInventors: Rosario Lizio, Michael Damm, Hans-Ulrich Petereit
-
Publication number: 20150024046Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
-
Patent number: 8932628Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 13, 2007Date of Patent: January 13, 2015Assignee: Valeant International BermudaInventors: Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
-
Publication number: 20140377345Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: ApplicationFiled: September 9, 2014Publication date: December 25, 2014Inventors: John McKearn, Jeremy Blitzer
-
Publication number: 20140356426Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.Type: ApplicationFiled: May 27, 2014Publication date: December 4, 2014Applicant: GRÜNENTHAL GMBHInventors: LUTZ BARNSCHEID, ANJA GEIßLER, KLAUS WENING, JANA PÄTZ
-
Patent number: 8900575Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.Type: GrantFiled: December 15, 2006Date of Patent: December 2, 2014Assignee: Oxthera Intellectual Property ABInventors: Qingshan Li, Harmeet Sidhu
-
Publication number: 20140341963Abstract: A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions.Type: ApplicationFiled: May 9, 2014Publication date: November 20, 2014Applicant: ActiveSignal Holding LimitedInventor: Ward Warren
-
Publication number: 20140341987Abstract: A changing colour composition for caring for and/or making up keratin materials on the form of an O/W emulsion comprising, in a physiologically acceptable medium, at least a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least 5% by weight, more preferably at least 8% by weight and advantageously at least 10% by weight relative to the weight of the composition of an aqueous phase comprising water and at least one compound chosen from polyols, glycols C2-C8 monoalcohols and mixtures thereof, c) non entrapped Ti02, and d) an O/W emulsifier.Type: ApplicationFiled: January 16, 2013Publication date: November 20, 2014Applicant: L'OREALInventors: Yihao Chai, XueDong Liu, Weiyi Guan, Qing Yu, Jing Chen
-
Patent number: 8889180Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.Type: GrantFiled: October 7, 2011Date of Patent: November 18, 2014Assignee: Western University of Health SciencesInventor: Guru V. Betageri
-
Publication number: 20140328911Abstract: The invention relates to compositions comprising a mixture of a pomegranate extract and an erectile dysfunction-treating compound. These compositions can be used to treat erectile dysfunction in men and sexual dysfunction in women. The pomegranate extract and the erectile dysfunction-treating compounds surprisingly and unexpectedly act in a synergistic manner, allowing the compositions to contain a lower amount of the pomegranate extract, the erectile dysfunction-treating compound, or both. The synergism of the two components of the composition results in a lower incident of side effects, as well as being less expensive. The invention also relates to products comprising a series of dosages of the compositions of the invention, wherein either the pomegranate extract or erectile dysfunction-treating compound can be raised or lowered, until a maintenance dosage level of the pomegranate extract and the erectile dysfunction-treating compound is reached.Type: ApplicationFiled: July 19, 2012Publication date: November 6, 2014Applicant: POM WONDERFUL. LLCInventor: Bradley K. Gillespie
-
Publication number: 20140328910Abstract: An ingestion method of creatine composition, taking orally the creatine composition with beverage, characterized in that, the creatine composition is taken orally by preparing creatine composition aqueous solution with dissolving the creatine composition over one minute into water heating at 80-100° C. and by mixing the creatine composition aqueous solution with the beverage having ordinary or cool temperature.Type: ApplicationFiled: November 9, 2012Publication date: November 6, 2014Inventors: Hirohisa Nishizawa, Haruhiko Sueoka
-
Publication number: 20140322316Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventor: Roland Saur-Brosch
-
Publication number: 20140322296Abstract: The present invention provides a microcapsule pharmaceutical composition of at least a bisquinoline drug. said microcapsule comprises a drug core of a pharmaceutically effective amount of a bisquinoline drug and a polymeric coating over the core. This microcapsule pharmaceutical composition has desirable pharmaceutical properties, including taste masking effect and a high stability.Type: ApplicationFiled: March 21, 2014Publication date: October 30, 2014Inventors: Christian Stollberg, Giancarla Bianchi, Flavio Fabiani, Luigi Boltri
-
Publication number: 20140322317Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Inventors: Christopher J. SPEIRS, Peter MOIR, Richard WILLIAMS, Michael CLARK
-
Publication number: 20140314843Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.Type: ApplicationFiled: April 17, 2014Publication date: October 23, 2014Applicant: Codexis, Inc.Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
-
Publication number: 20140314844Abstract: The present invention relates to an oral complex formulation comprising omega-3 fatty acid or its derivatives encapsulated in a hard or soft capsule containing sorbitol and sorbitan, as well as an HMG-CoA reductase inhibitor. The formulation of the present invention comprising omega-3 fatty acid encapsulated with sorbitol and sorbitan provides better prevention related materials from being formed, leading to improved long-term storage stability. The oral complex formulation of the present invention also can raise the serum HDL-cholesterol level, while reducing both LDL-cholesterol and TG levels. The oral complex formulation of the present invention is useful for treatment of hyperlipidemia.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: HANMI PHARM. CO., LTDInventors: Jin Cheul Kim, Jae Ho Kim, Eun Jin Yoon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
-
Patent number: 8865190Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: April 1, 2014Date of Patent: October 21, 2014Assignee: Pozen Inc.Inventor: John R. Plachetka